This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stojadinovic, A. Articles by Brennan, M. F. Search for Related Content PubMed PubMed Citation Articles by Stojadinovic, A. Articles by Brennan, M. F.

Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization

From the Departments of Surgery and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Ronald A. Ghossein, MD, Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021; email: ghosseir{at}mskcc.org

PURPOSE: To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters.

PATIENTS AND METHODS: Clinical data were analyzed for 124 patients, histopathologic slides for 67 primary tumors, and tissue specimens for 74 patients (38 primary and 36 metastatic tumors) with ACC and for 38 normal adrenal tissue samples. Molecular expression profiles were investigated by immunohistochemistry. The prognostic significance of 12 gross and histologic parameters in 67 primary ACCs was evaluated. Morphologic and protein expression patterns were correlated with disease-specific survival (DSS). Univariate influence of prognostic factors on DSS was analyzed by log-rank test and multivariate analysis by Cox regression.

RESULTS: The median follow-up period was 4.7 years. Significant predictors of DSS included distant metastasis at time of initial presentation; venous, capsular, and adjacent organ invasion; tumor necrosis, mitotic rate, atypical mitosis, and mdm-2 overexpression. Five-year DSS by number (one to six) of adverse histologic parameters was as follows: one to two, 84%; three to four, 37%; more than four, 9% (P = .005).The phenotype Ki-67(-)p53(-)mdm-2(+)cyclinD1(-)Bcl-2(-)p21(-)p27(+) was observed in 83% of normal and 3% of malignant adrenal tissue (P = .01). Molecular phenotypic expression was more heterogeneous in malignant than in normal (10 v five phenotypes) adrenal tissue.

CONCLUSION: Meticulous morphologic evaluation, mitotic count, and tumor stage are essential in determining prognosis for patients with ACC. Multimolecular phenotyping demonstrates that the molecular complexity and heterogeneity of these neoplasms are such that targeted therapy needs to be patient specific.

Both A.S. and R.A.G. contributed equally to this work.

This article has been cited by other articles:

				A Advani, S Vaikkakara, M S Gill, C S Arun, S H Pearce, S G Ball, R A James, T W J Lennard, R D Bliss, R Quinton, et al. Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review J. Clin. Pathol., August 1, 2008; 61(8): 939 - 944. [Abstract] [Full Text] [PDF]

				M Volante, C Buttigliero, E Greco, A Berruti, and M Papotti Pathological and molecular features of adrenocortical carcinoma: an update J. Clin. Pathol., July 1, 2008; 61(7): 787 - 793. [Abstract] [Full Text] [PDF]

				P. S. H. Soon, K. L. McDonald, B. G. Robinson, and S. B. Sidhu Molecular Markers and the Pathogenesis of Adrenocortical Cancer Oncologist, May 1, 2008; 13(5): 548 - 561. [Abstract] [Full Text] [PDF]

				M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380. [Abstract] [Full Text] [PDF]

				R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]

				S. Ohwada, M. Izumi, S. Kawate, K. Hamada, H. Toya, N. Togo, J. Horiguchi, Y. Koibuchi, T. Takahashi, and M. Yamada Surgical Outcome of Stage III and IV Adrenocortical Carcinoma Jpn. J. Clin. Oncol., February 2, 2007; (2007) hyl127v1. [Abstract] [Full Text] [PDF]

				G. Assie, G. Antoni, F. Tissier, B. Caillou, G. Abiven, C. Gicquel, S. Leboulleux, J.-P. Travagli, C. Dromain, X. Bertagna, et al. Prognostic Parameters of Metastatic Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 148 - 154. [Abstract] [Full Text] [PDF]

				M. Fassnacht, S. Hahner, B. Polat, A.-C. Koschker, W. Kenn, M. Flentje, and B. Allolio Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4501 - 4504. [Abstract] [Full Text] [PDF]

				B. Allolio and M. Fassnacht Adrenocortical Carcinoma: Clinical Update J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2027 - 2037. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 920 - 925. [Abstract] [Full Text] [PDF]

				L. S. Kirschner Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21. [Abstract] [Full Text] [PDF]

				C. Francois, B. Rangachari, and D. Bova Mammography and Sonography of Pathologically Proven Adrenal Cortical Carcinoma Metastatic to the Breast Am. J. Roentgenol., April 1, 2005; 184(4): 1279 - 1281. [Full Text] [PDF]

				P. Labelle, A. E. Kyles, T. B. Farver, and H. E. V. De Cock Indicators of Malignancy of Canine Adrenocortical Tumors: Histopathology and Proliferation Index Vet. Pathol., September 1, 2004; 41(5): 490 - 497. [Abstract] [Full Text] [PDF]

				G. Mansmann, J. Lau, E. Balk, M. Rothberg, Y. Miyachi, and S. R. Bornstein The Clinically Inapparent Adrenal Mass: Update in Diagnosis and Management Endocr. Rev., April 1, 2004; 25(2): 309 - 340. [Abstract] [Full Text] [PDF]

				E. Michalkiewicz, R. Sandrini, B. Figueiredo, E.C.M. Miranda, E. Caran, A.G. Oliveira-Filho, R. Marques, M.A.D. Pianovski, L. Lacerda, L.M. Cristofani, et al. Clinical and Outcome Characteristics of Children With Adrenocortical Tumors: A Report From the International Pediatric Adrenocortical Tumor Registry J. Clin. Oncol., March 1, 2004; 22(5): 838 - 845. [Abstract] [Full Text] [PDF]

				C. A. Koch, K. Pacak, and G. P. Chrousos The Molecular Pathogenesis of Hereditary and Sporadic Adrenocortical and Adrenomedullary Tumors J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5367 - 5384. [Abstract] [Full Text] [PDF]